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Role of observational studies versus clinical trials in ESRD since it is nonrandom due to selection and exclusion
research. Randomized controlled clinical trials have been con- criteria. For example, patients may be excluded for lack
sidered by many to be the only reliable source for information of consent or for noncompliance. An example of thisin health services research. This review considers the advan-
problem can be found in the Modification of Diet andtages and limitations of observational studies as compared to
Renal Disease Study (MDRD), where the randomiza-randomized clinical trials. It presents specific examples of scien-
tific research done with observational registry data to show tion to a low protein and a very low protein diet excluded
that some research is more feasible with an observational ap- a large fraction of patients because of the difficulties in
proach and that this approach may lead to better designs of
following severe dietary restrictions [2]. Therefore, thisprospective clinical trials. Such trials continue to be the gold
study can be extrapolated only to those patients whostandard in outcomes research.
would be able and willing to follow such a strict diet,
while it may not be applicable to other patients. This
and similar studies observe the efficacy of a treatment,Much of the research in ESRD has been based on
i.e., what the treatment A vs. treatment B can accomplishobservational studies, and a large portion of the scientific
(perhaps under ideal circumstances).knowledge in this field comes from registry studies. Nu-
In contrast, many population-based observationalmerous national and regional registries of patients
studies select patients at random and the treatment as-treated for ESRD are currently in existence [1]. The
signment is nonrandom. Such studies may thus be repre-purpose of this review is to assess the advantages and
sentative of all patients. If, for example, children werelimitations of observational studies compared to ran-
excluded, then the results would still be representative,domized, controlled, clinical trials in research that fo-
but only of adult patients. The emphasis of such studiescuses on outcomes. The following review and discussion
is to evaluate the efficiency of treatment A vs. treatmentwill focus particularly on observational studies that are
B as delivered under real world conditions, which maypopulation-based, such as studies of registries, although
be less than ideal and include patients who are not com-much of the discussion is also relevant for larger single-
pliant. The findings of such a study are more easily ex-or multicenter studies. Examples will largely be drawn
trapolated to the population at large (while consideringfrom USRDS studies.
applicable exclusion criteria). Control for confounding
factors is limited to those factors that are recognized and
PATIENT AND TREATMENT ASSIGNMENT measured, while adjustment for unknown factors is not
One of the most basic differences between observa- possible.
tional studies and randomized controlled clinical trials
lies in the design and assignment of patients and treat-
TIME TO COMPLETION OF STUDYments. In the randomized, controlled trial, the treatment
assignment is random, i.e., patients are assigned ran- Truly prospective observational studies and random-
domly to one treatment or another. An advantage of the ized controlled trials may require a similar time frame to
random assignment is the control of confounding factors completion. However, observational studies of historical
both known and unknown. The assignment of patients, cohorts can be completed within a substantially shorter
however, usually is not representative of all patients, time frame. This retrospective approach may allow the
study to begin at a time in the past, and all follow-up of
interest may already be available at the time of data
abstraction. This design may be labeled “historically pro- 2000 by the International Society of Nephrology
S-3
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spective” if the data collection follows strict rules for causes of death could be identified as being responsible
for the overall correlations with Kt/V [13], membraneabstracting baseline data while not allowing any data
after the baseline date to enter consideration, except, of [14] and hyperphosphatemia [15]. Thus, a single observa-
tional study on a random sample of about 5000 hemodia-course, the outcome(s) of interest. The ascertainment of
coronary artery disease at study start may serve as an lysis patients led to important new knowledge with re-
spect to several hypotheses. Even lacking results from aexample: A patient with no evidence in the medical re-
cords at study start may, a week later, be admitted with prospective trial, these results have had an impact on
dialysis practice and likely on patient survival in thean acute myocardial infarction. Even though this new
evidence indicates that coronary artery disease must United States [16].
have been present at study start, the prospective ap-
proach requires coding of coronary disease as being ab-
COSTsent at study start because evidence was lacking at that
Prospective randomized clinical trials tend to be verytime. Thus, a historical prospective study is designed like
costly. The recent MDRD and HEMO trials are exam-a prospective study with a fixed study start date, located
ples of high cost trials. It appears that cost may be ain the past, using only data that would have been avail-
reason why major trials in ESRD are launched infre-able at or before that date. This approach saves the time
quently. Observational studies of existing registries areof waiting for the outcome events to accumulate during
of comparatively low cost. In the USRDS, data collec-the follow-up period, as the follow-up period of interest
tions on random samples of patients have occured almostis already available. However, a critical ingredient is that
on a yearly basis, and each such data collection has testedthe availability of data (e.g., of medical records) must
several hypotheses. Observational study results also maynot vary according to the study outcome. This historical
be cost effective by helping to focus questions for ran-prospective approach has been successfully utilized by
domized trials and estimating the size of the expectedmany studies of the United States Renal Data System
effect. The latter is required for the calculation of the(USRDS) [3–5].
needed sample size. For example, the HEMO trial is
evaluating the effect of two levels of dialysis dose [6],
NUMBER OF HYPOTHESES both being at a level above which the USRDS studies
Clinical trials frequently test only one or two main could not determine whether the dialysis dose was still
hypotheses, sometimes with some secondary goals. Ob- correlated with mortality [7, 17].
servational studies may be designed to test numerous Because of the large costs of prospective randomized
hypotheses. The Hemodialysis (HEMO) Trial may serve trials in dialysis, the sample size for most such studies
as an example of the former with two hypotheses that was barely adequate. The National Cooperative Dialysis
dialysis dose and dialysis membranes are each indepen- Study (NCDS) may serve to make that point; most who
dently associated with outcomes [6]. Testing a third hy- examined the study data concluded that shorter treat-
pothesis would have required eight study groups instead ment time was not associated with worse outcomes in a
of four for this trial. statistically significant fashion (P . 0.05) [18]. However,
The USRDS Case Mix Adequacy Study may serve as this correlation in fact had a P value of 0.06, suggesting
an example of many hypotheses tested in a single sam- that a slightly larger sample size might have led to a
pling frame and data collection instrument. When ad- significant conclusion, namely that longer hemodialysis
justing for patient demographics, comorbid conditions, treatment times were associated with better outcomes.
and selected laboratory values, this study evaluated mor- This last major dialysis trial in the U.S. was performed
tality risk as the primary outcome by dialysis dose, type about 20 years ago. The next major clinical trial in U.S.
of membrane, nutrition, control of phosphorus and other dialysis patients is the current HEMO trial. The MDRD
factors. The main findings included a strong correlation trial on pre-ESRD patients had a cost that exceeded
of lower dialysis dose with higher mortality risk [7], a the entire USRDS budget with all its studies, numerous
correlation of dialyzer membrane with mortality even at reports and scientific publications in the last 11 years.
the same dialysis dose [8], a correlation of nutritional Therefore, it appears from my vantage point (perhaps
status with mortality risk even after a several year lag biased) that observational studies complement major tri-
period [9], a correlation of hyperphosphatemia with mor- als and often yield clinically useful information at a sub-
tality risk [10] with and without adjustment for nutrition, stantially lower cost.
and dialysis dose [11], as well as compliance (Leggat)
and a correlation of low middle molecule clearance (mea-
CAUSATION AND CORRELATIONsured by vitamin B12) with high mortality risk, even at
the same Kt/V for urea [12]. Additional studies [6–8] Double-blind, randomized trials allow inference of
causality if the trial is well designed, the result is positive,looked at cause-specific death rates to ascertain which
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and power is sufficient, i.e., there is a statistically signifi- Observational studies can be performed in areas where
prospective trials have ethical restrictions. Both clinicalcant result. Observational studies like those of the
USRDS only report associations; however, they have trials and observational studies therefore have specific
roles. They may complement one another, as when theaffected clinical practice in the U.S. and perhaps else-
where. One may argue that observational study results observational study leads to a hypothesis, which can be
answered in a well-designed clinical trial. Furthermore,of USRDS and others have been responsible for the
marked improvement in the survival of dialysis patients data from an observational study may help develop a
new trial by suggesting sample size requirements and[16]. Reasons for acceptance of observational study re-
sults in clinical practice include the magnitude of the optimal design.
observation and the pathophysiologic plausibility. Addi-
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